Limited responsiveness to IFN-α in hepatitis C virus (HCV)-infected African-Americans compared to European Americans (AAs vs. EAs) hinders the management of HCV. Here, we studied healthy non-HCV-infected AA and EA subjects to test whether immune cell response to IFN-α is determined directly by race. We compared baseline and IFN-α-induced signal transducer and activator of transcription (STAT)-1, STAT-2, STAT-3, STAT-4, and STAT-5 protein and phosphorylation levels in purified T cells, global transcription, and a genomewide single-nucleotide polymorphism (SNP) profile of healthy AA and EA blood donors. In contrast to HCV-infected individuals, healthy AAs displayed no evidence of reduced STAT activation or IFN-α-stimulated gene expression compared to EAs. Although >200 genes reacted to IFN-α treatment, race had no impact on any of them. The only gene differentially expressed by the two races (NUDT3, P < 10
) was not affected by IFN-α and bears no known relationship to IFN-α signaling or HCV pathogenesis. Genomewide analysis confirmed the self-proclaimed racial attribution of most donors, and numerous race-associated SNPs were identified within loci involved in IFN-α signaling, although they clearly did not affect responsiveness in the absence of HCV. We conclude that racial differences observed in HCVinfected patients in the responsiveness to IFN-α are unrelated to inherent racial differences in IFN-α signaling and more likely due to polymorphisms affecting the hosts' response to HCV, which in turn may lead to a distinct disease pathophysiology responsible for altered IFN signaling and treatment response.
African-American | European American | microarray | signal transducers and activators of transcription | hepatitis C virus C urrent treatment of chronic hepatitis C virus (HCV) infection relies on combinational therapy with the antiviral cytokine IFN-α and the antiviral nucleoside analog ribavirin. A major factor affecting success of therapy is the HCV-infected hosts' responsiveness to IFN-α. HCV-infected African-Americans (AAs) exhibit limited responsiveness to IFN-α compared to other races, such as European Americans (EAs), resulting in a massively diminished AA:EA odds ratio for achievement of sustained virological response (1) (2) (3) (4) (5) . In line with this clinical reality, peripheral blood mononuclear cells (PBMC) of HCVinfected AA patients display limited signal transducer and activator of transcription (STAT)1 phosphorylation compared with EA patients and an altered gene expression profile upon stimulation with IFN-α ex vivo (2) . These observations led to the hypothesis that the geo-ethnic background of Americans might impact IFN-α signaling upstream of STAT1 and compromise responsiveness of AAs to therapy.
Interestingly, polymorphisms of genes involved in type I IFN signaling or function have been associated with racial differences in the outcome of chronic HCV infection (6) . Furthermore, HCV infection suppresses IFN-α signaling, and HCV viral particles are capable of suppressing STAT1 transcription and phosphorylation, decreasing its half-life and inhibiting nuclear transport and DNA binding of activated STAT1 (7) . Hence, in HCV-infected individuals, it is difficult to conclusively test whether the poor response of AAs to IFN-α/ribavarin treatment and their impaired response to IFN-α ex vivo is due to a genetic trait that directly affects IFN signaling or is secondary to a differential effect of HCV infection on the immune response of AAs compared to EAs. Moreover, in HCV-infected patients it is not possible to separate race-dependent markers of IFN-α responsiveness from genetic polymorphisms indirectly affecting resistance to viral infection or resistance to viral interference with IFN-α signaling. In this study, we provide evidence that in the absence of HCV infection, race does not affect ex vivo IFN-α responsiveness. Racial traits affecting IFN-α treatment in HCV infection may be restricted to polymorphisms in genes directly interacting with or affected by HCV during the natural history of the disease.
Results
IFN-α Signal Transduction Is Highly Conserved Between Healthy AA and EA. STAT1 phosphorylation (STAT-P) is a key component of the Janus kinase (JAK)-STAT signaling pathway correlated to the activation of IFN-stimulated genes (ISGs) (8) . Altered phosphorylation of STAT1 in response to IFN-α stimulation of PBMC in vitro was proposed as a predictor of poor responsiveness to therapy of HCV with the same agent particularly in AAs (2) . Therefore, we compared STAT-P induction between healthy EAs and AAs. Pilot studies in our lab confirmed published reports (9) that among all PBMC subpopulations, T cells and monocytes express STAT1 at the highest level and phosphorylate it most efficiently upon IFN-α stimulation (Fig. S1 ) and that the 200 IU/mL concentration commonly used for PBMC stimulation is roughly equivalent to that required for the ED 50 of STAT1 phosphorylation in T cells (ED 50 IFN-α = 213 IU/ Author contributions: Z.P., S.F.L., E.W., H.J.A., and F.M.M. designed research; Z.P., S.S., T.L.S., J.K.W., H.L., and A.W. performed research; Z.P., T.L.S., M.S., A.M., E.W., and F.M.M. contributed new reagents/analytic tools; Z.P., E.W., and F.M.M. analyzed data; and Z.P., S.F.L., A.F., H.J.A., and F.M.M. wrote the paper.
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Data deposition: The data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE17952). mL; Fig. S2 ). On the basis of this observation, the critical role of T cells in resolving HCV infection (10) , and their relative abundance compared to monocytes, we used T cells purified by negative selection.
In contrast to the marked differences observed in HCVinfected patients (2), STAT1-P fold change (FC) upon IFN-α stimulation was not significantly different between healthy AA and EA donors (Fig. 1B) , nor were baseline and induced STAT1-P levels or levels of STAT1 protein (Fig. 1C) . In addition, race did not affect responsiveness as measured by ratios of STAT1-P or STAT1-positive cells in control and IFN-α-affected samples (Fig. S3 ). The only difference observed between the two ethnic groups was intraracial response heterogeneity, which was found to be greater in AAs, compared to EAs. By arbitrarily splitting the response phenotype into low, medium, and high (STAT1-P FC <1.5, 1.5-3.0, and >3.0, respectively), AA values scattered in a uniform distribution among all categories, whereas EA values prevailed in the medium response group (Fig. 1B , P = 0.028, χ 2 -test). In smaller substudies comparing 12 donors from each of the two races, we evaluated all other STAT proteins known to be affected by IFN-α in T cells (STAT2, STAT3, STAT4, and STAT5). We found no significant differences between races in baseline or induced STAT phosphorylation levels, STAT protein levels ( Fig. 1 B and C) , or the ratio of STAT or STAT-P positive cells (Fig. S3) . Moreover, baseline and IFN-α-induced STAT protein phosphorylation levels and phosphorylation fold changes were highly variable and showed generally poor correlation among STAT proteins (with the exception of STAT1-P and STAT3-P; R 2 = 0.522, P value <0.001), clearly challenging the assumption that STAT1 phosphorylation can exclusively represent the complexity of the IFN-α response ex vivo ( Fig. 1 A  and D) .
To test whether the lack of racial difference in IFN-α-induced STAT1-P in healthy individuals was limited to IFN-α, T cells were treated with cytokines using signaling mechanisms similar to IFN-α (IFN-β), highly similar intracellular signaling but distinct receptor usage (IFN-λ), overlapping at one or more levels of the JAK/STAT pathway (IL-2 and IFN-γ), or, as a negative control, unrelated to IFN-α signaling (IL-4). No race-associated difference in induced STAT1 phosphorylation was observed regardless of the cytokine tested ( Fig. 2A) . However, we observed that induced STAT1-P FC was highly correlated among cytokines, underlining the limited specificity of STAT1-P FC as a marker of in vitro IFN-α responsiveness ( Fig. 2 B-E) . Finally, in line with others' observations (11), we observed that CD3 + T cells' in vitro responsiveness to IFN-λ is very limited ( Fig. 2A) . 
Healthy Individuals Exhibit Activation of ISGs Regardless of Race.
Global gene expression profiling was used to identify genes whose expression could be affected by race, IFN-α treatment, both race and treatment, or interactions between race and treatment. To optimize the trade-off between size and reproducibility/reliability of the list of differentially expressed genes (DEGs), several fold change cutoff values (FC >1, >1.5, and >2.0 in >25% of all samples) and various P-value criteria (P < 10 ) were tested by analyzing a "training" array set (Table 1) , using mixed-effects model ANOVA. The resulting gene lists were retested on a second, nonoverlapping "test" array set (Table 1) for their reproducibility, i.e., their ability to reproduce sample separation by major experimental factors (race, treatment) in an independent sample set by unsupervised hierarchical clustering.
In general, gene sets defined by FC >1.5 and P < 10 −7 were found to be the most reproducible at this sample size and composition (156 arrays total), while still containing the most comprehensive DEG list. Using these criteria, IFN-α treatment affected 222 transcripts (205 annotated, Fig. 3A , see Table S1 for detailed annotation and expression data). Pathway analysis of genes significantly affected by IFN-α treatment confirmed functional reliability of these findings, disclosing that these ISGs constitute canonical gene networks involved in well-known IFNaffected processes, such as IFN-α signaling, protein ubiquitination, antigen presentation, and intracellular recognition of viral pathogens, etc. (Table 2 ).
In contrast, race was found to have virtually no impact on the gene expression profile of the analyzed samples, as there was only one transcript that was both significant and reproducibly different between races. The only transcript affected by race was NUDT3, whose expression was decreased in AAs. NUDT3 is a gene involved in nucleoside metabolism, playing a role in the removal of some toxic nucleotide metabolites, expressed almost ubiquitously in all human tissues, but with no known relationship to HCV infection, IFN-α signaling, antiviral responses, or other immune-related processes. Hence, ethnic differences in NUDT3 expression are unlikely to explain the differential response to IFN-α of HCV-infected individuals. In summary, our data suggest a marked dissociation between the number of race-affected genes compared to IFN-α-induced genes in healthy donors. Interestingly, this dissociation remained highly consistent regardless of statistical selection criteria of DEGs (Fig. 4A) .
Moreover, genes potentially affected by race did not overlap with IFN-α-affected genes at any FC or α-levels chosen for analysis (Fig. 4A) ; in addition, mixed-effects model ANOVA confirmed that there were no genes affected by an interaction between race and IFN-α treatment (genes expressed at different levels depending on race only before or after IFN-α treatment) at any α-levels and FC criteria used (Fig. 4A) . In contrast to HCV-infected patients, race did not affect average fold change of ISGs in healthy donors (Fig. 4B) . As opposed to IFN-α treatment, race had virtually no effect on the ISG expression profile as judged by unsupervised hierarchical clustering or multidimensional scaling (Fig. 4 C and D) .
IFN-α-Independent Activation of a Subgroup of ISGs Accounts for
Baseline Heterogeneity Among Healthy Donors. Whereas ISG expression following IFN-α stimulation was consistent among individuals of either race, clear heterogeneity was observed in the expression of a subgroup of ISGs in baseline conditions (unstimulated T cells). As in chronic HCV, pretreatment activation of prominent classical ISGs and canonical ISG pathways has been reported to be associated with nonresponse to IFN-α therapy (12, 13) . We decided to further analyze unstable ISGs in detail. In contrast to HCV-infected patients, this subgroup of transcripts (further referred to as baseline unstable ISGs, Fig. 3  A and B) included genes whose function is not directly associated with canonical IFN-regulated pathways, whereas the rest of the ISGs (designated as baseline stable ISGs) were selectively regulated by IFN-α stimulation (see Table S2 for lists of baseline stable and unstable ISGs). Comparative analysis of the training and test sample sets by hierarchical clustering confirmed that this phenomenon affected a reproducible set of genes in both the training and the test sample sets analyzed (Fig. 3 A and B) . Ingenuity pathway analysis (IPA) suggested that baseline unstable ISGs of healthy individuals covered different aspects of cellular metabolism, in sharp contrast with baseline stable ISGs The master set includes all donors analyzed in this study, and the training and test sets represent two nonoverlapping halves of the master set; all donors of the master, training, and test sets are represented by one single blood donation in all analyses. Blood donations of the third repeat set were derived from donors donating twice in two random independent time points over a period of 1 year; in this set, each donor is represented by two donations. Statistical group (sample) size of sample sets (n) is equal to (the number of donors) × (number of donations/donor) × (2), as each donation has been split into a control and an IFN-α-treated parallel in all analyses.
clearly associated with canonical IFN-α signaling pathways such as protein ubiquitination, antigen presentation, and JAK-STAT signaling, etc. (Table 2 ). Hence, gene expression analysis suggests that immunity-related core IFN-α functions are relatively homogenously activated by IFN-α in healthy individuals and are, in general, inactivated in baseline conditions. Most individual heterogeneity is present in genes associated with diverse nonimmune cellular functions exerted by IFN-α, predominantly those related to metabolic processes. We next analyzed whether preactivation of the baseline unstable ISG module was a stable phenotype for a discrete set of individuals. Using the repeat sample set, consisting of repeated collections derived from the same donors at different time points, we observed that activation of baseline unstable ISG was not idiosyncratic and could vary at different donations from the same individual over time (Fig. 3C) ; thus, baseline variations in unstable ISGs are also unlikely to be genetically determined.
We found that STAT1-P FC showed very limited correlation with ISG expression. Individuals with low, medium, and high STAT1-P FC values presented some limited coclustering, but no striking separation by ISG expression patterns (Fig. 4C) . Consistent with this, multidimensional scaling revealed that lower numbers of STAT1-P-positive cells usually lead to weaker responses at the ISG induction (P < 0.001); however, generally this marker was not able to predict the response at the ISG level (Fig. S4) .
Whole-Genome SNP Profiling Confirms Racial Identity and Discloses a
List of Race-Associated Polymorphisms of ISGs. Whole-genome SNP profiling was used to analyze the distribution of SNP patterns between EAs and AAs, with particular focus on IFN-α-related genes. It has been shown recently that Africans residing in Africa can be heterogeneous at the SNP level, showing distinct separation from other non-African ethnic groups, whereas AfricanAmericans have a more homogeneous West African origin and are often admixed to non-African populations (14) . Thus, a confirmation of the self-proclaimed ethnicity of individual donors was deemed necessary to enhance the accuracy of our study. Whole-genome SNP arrays corresponded accurately to the subjective racial self-identification of donors; analysis of 848,365 SNPs that passed instrumental and methodological quality control (QC) criteria (of ∼960,000 present in the array platform) clustered donors according to their self-proclaimed race with only two exceptions (Fig. 5A , two self-proclaimed AAs clustering with EAs). Finally, DNA samples of blood donors whose samples were obtained on two different occasions clustered together and displayed a virtually identical genotype in repeat samples (Fig. 5B) .
Race bore a huge impact on the SNP profile, resulting in the identification of 26,026 SNPs specific to the AA population, more or less evenly distributed along the genome (Fig. 5C) [as 848,365 SNPs passed the QC filters, the P value after the −Log(P value) indicates significance of association with a canonical Ingenuity pathway; the eight most significant pathways are shown. Ratio values are calculated by dividing the number of genes that meet cutoff criteria by the total number of genes that make up the pathway. Bonferroni correction for multiple testing (0.05/848,365) was P < 5.89 × 10E −8 ; see Dataset S1 for a full list of SNPs linked to race]. Concordantly, of the 5,320 SNPs linked to the 222 ISGs identified by gene expression profiling, many were affected by race (see full list of 158 SNPs associated to both race and ISGs in Dataset S2). These findings are remarkable, considering that in spite of the relatively large number of race-linked SNPs in ISGs, none had a significant racial impact on the mRNA-level expression of its associated gene.
Finally, it was proposed that chromosome 19 contains a hotspot of several SNPs strongly affecting IFN-α responsiveness in chronic HCV infection and spontaneous HCV clearance (15) (16) (17) , most of them associated to the IL28B/A (also known as IFN-λ 3/2) region; thus, additional analysis was performed focusing on this region. Although race-linked SNPs are numerous, and evenly distributed on chromosome 19 (Fig. 5D) , we did not find significant differences between healthy EAs and AAs in the SNPs genotyped in the IFN-λ 3/2 region (Fig. 5E ).
Discussion
Our study shows that previously reported racial differences in responsiveness to IFN-α under pathological conditions are not present in healthy individuals. Thus, differences in clinical response to IFN-α between HCV-infected AAs and EAs are not due to an inherent defect(s) in the signal transduction machinery or the transcriptional regulation of ISGs downstream of IFN-α signaling, but rather to the way AAs interact with or respond to HCV and how extensively or rapidly this response changes over Samples are color coded for treatment (purple, control; pink, IFNa), race (pale blue, European; yellow, African-American), and STAT1-P FC (pale gray, low STAT1-P FC; medium gray, medium STAT1-P FC; dark gray, high STAT1-P FC). (D and E) Results of a similar analysis after reduction of ISG data complexity to three dimensions (x, y, and z) by multidimensional scaling (MDS). MDS reveals that axis x, representing the principal difference between all samples, is bona fide equivalent with the IFN-α treatment effect, whereas race is virtually irrelevant. (E) None of the SNPs detected in the hotspot region (blue frame) was significantly linked to race. In C-E, the y axis indicates uncorrected P values, whereas horizontal red lines indicate Bonferroni-corrected significance thresholds, equivalent to a global P value of P < 0.05.
time during the course of infection. The key determinant could be how racial polymorphisms interact with the virus or virusdrug interactions rather than with the drug itself. Among possible explanations, both races may react to IFN-α similarly but (i) HCV suppresses IFN-α signaling in AAs more efficiently than in EAs, (ii) the immune response to HCV among AAs is somehow different, creating a difference in the course of the disease that results in a decreased efficiency of IFN-α, or (iii) patients with chronic HCV infection represent a population different from healthy individuals or blood donors, and hence the genetic background of the one is not representative for the other.
Our findings are in line with the recent observation (15-17) that in chronic HCV patients, responsiveness to IFN-α therapy is not affected by SNPs related to IFN-α or IFN-α-stimulated genes, but strongly influenced by those associated to IFN-λ loci. Likely, variants of IFN-λ, which is highly expressed in hepatocytes, may differentially alter the biology of HCV infection in the liver and at the systemic level, which, in turn, may influence the responsiveness of immune cells to IFN-α stimulation. The finding that IFN-λ SNPs also affect spontaneous clearance of the virus (18) suggests that genetic differences can affect disease course from very early phases of HCV infection independent of therapy, hence indirectly affecting the outcome of IFN-α therapy.
Recently, others reported that lymphocytes and other circulating mononuclear cells from patients with cancer suffer reduced phosphorylation of STAT proteins in response to . This phenomenon is observable at later stages of cancer progression (stage II to IV), suggesting that a sufficient bulk of tumor needs to be present to induce systemic effects. It is, therefore, possible that a chronic inflammatory process, whether induced by chronic viral infection or by cancer, may be responsible for the altered innate immune responses and that AAs may be more susceptible in the context of HCV infection. Interestingly, these authors observed that alterations in STAT protein phosphorylation affect most PBMC subpopulations and they are predominantly pathway specific rather than cell-type specific. Although we did not address all PBMC populations and focused on the most commonly investigated T cell population, it is likely that these findings could be generalized on the basis of others' experience.
Materials and Methods
Detailed methods are available in SI Materials and Methods.
Blood Samples. Ninety-six consecutively collected blood donations, donated for research purposes with informed consent, were collected from 78 healthy EA and AA donors by the Department of Transfusion Medicine, Clinical Center, National Institutes of Health with Institutional Review Board approval (n = 78, Table 1 ).
Sample Processing and Treatments. Whole blood samples were processed by leukapheresis and Ficoll density gradient centrifugation, and untouched T cells were isolated by magnetic-bead associated cell sorting, using Miltenyi's Human Pan T cell isolation kit for negative selection. T cell purity was checked by staining CD3 + cells for flow cytometry and found to be 92-95%. Cells were stimulated with IFN-α 2b (200 IU/mL) for 15 min for flow cytometry or 6 h for gene expression profiling.
Flow Cytometry. Cells were double stained for intracellular STAT1, -2, -3, -4, and -5 protein levels and STAT1, -2, -3, -4, and -5 phosphorylation after fixation with paraformaldehyde (PFA) and subsequent methanol permeabilization (see Table S3 for details). Statistical evaluation was done using Student's t test or the Mann-Whitney rank sum test to compare means, the chi-square test to compare the distribution of races between IFN-α response phenotypes, and Pearson's correlation for correlation studies.
Gene Expression Arrays. Total RNA was processed by a two-cycle amplification procedure as described elsewhere (20) and hybridized to whole-genome human 36K oligo arrays, representing 25,100 unique human genes of the Operon Human Genome Array-Ready Oligo Set version 4.0, printed in house, using oligos purchased from Operon. ArrayBRB's mixed-effects model ANOVA was used to identify genes significantly affected by race, IFN-α treatment, or interaction between race and treatment. Functional gene network analysis was performed using the Ingenuity pathway analysis system.
Whole-Genome SNP Arrays. Genomic DNA was subjected to array-based SNP analysis, using Affymetrix's Genome-Wide Human SNP Nsp/Sty Assay Kit 6.0 per manufacturer's instructions. Data were analyzed using the SNP association analysis module of the Partek GS software package. SNP association to experimental categories such as race, treatment response, etc., was defined by performing χ 2 -tests using the allele association model of Partek GS.
